Cadila Healthcare on Monday said it has received a warning letter from the USFDA for its Moraiya-based formulation facility. The company said it has already taken multiple steps after the inspection by the USFDA and would continue to take all necessary steps in future as well to ensure that the health regulator is fully satisfied with its remediation of the above facility. The warning letter does not affect the existing business of the company in the US, Cadila Healthcare added.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.